Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones

PULSE BIOSCIENCES, INC.

Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.
Employment: $725k base salary, 70% target bonus, and option to purchase 1.5M shares at $18.43.
Options vest 30% time-based over 4 years; 70% performance-based tied to market cap ($3B–$9B) and GAAP revenue/margin targets.
Company also granted inducement options for 138,800 shares to 11 new employees at $18.55.
Pulse to present at JP Morgan Healthcare Conference Jan 15; nano-PFA cardiac systems in clinical studies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul A. LaViolette

Chief Executive Officer and President

PLSE · PULSE BIOSCIENCES, INC.

Effective: 2025-01-09
Filed: January 13, 2025, 6:59 PM ET

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul A. LaViolette was appointed as Chief Executive Officer and President at PULSE BIOSCIENCES, INC..

Action: appointed
Role: Chief Executive Officer and President

Exact text from the filing

The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025

View on SEC.gov

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-25-001006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.